cefotaxime and Carcinoma--Squamous-Cell

Ceftizoxime (CZX) was given in daily doses of 4 approximately 6 g by intravenous drip infusion to 30 patients with infection accompanying lung cancer to investigate the usefulness of the drug for infectious disease: The rate of effectiveness (marked and moderate) was 73.3% (22/30 patients). Of the 30 patients, 2 had drug fever; 1, arthralgia; and 1, eosinophilia. These side effects improved after the drug was withdrawn. CZX is a very useful antibiotic with high effectiveness and safety in immunocompromised patients with infection accompanying advanced lung cancer.

Topics: Adenoma; Adult; Aged; Bacterial Infections; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cefotaxime; Ceftizoxime; Female; Fever; Humans; Lung Neoplasms; Male; Middle Aged; Pneumonia; Pyelitis; Respiratory Tract Infections

Seven patients who were performed thoracotomy for the disease of the chest, were administered cefotiam dihydrochloride 2.0 g for about an hour by intravenous drip infusion during their operation. Antibiotic levels of serum and intrathoracic tissues (a piece of lung parenchyma, parietal pleura, pulmonary hilar lymph node, chest wall muscle, pulmonary cyst and nerve) were determined, and an evaluation of bactericidal effect was discussed. In this study, we found that antibiotic level of poor blood supplied lung, so called the destroyed lung was remarkably high. This means that a high concentration of cefotiam dihydrochloride to intrathoracic tissue is effective against postoperative infection.

Topics: Adult; Aged; Carcinoma, Squamous Cell; Cefotaxime; Cefotiam; Female; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Premedication; Surgical Wound Infection; Tuberculosis, Pulmonary